Appendix 3Y x 4
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
PharmAust Limited
ABN
35 094 006 023
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Dr Roger Aston
Date of last notice
9 November 2021
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
31 October 2023
No. of securities held prior to change
15,044,815 Ordinary Fully Paid Shares
3,649,904 Listed Options 31/10/2023 – 20c
Class
Listed Options 31/10/2023 – 20c
Number acquired
Number disposed
Nil
3,649,904
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
15,044,815 Ordinary Fully Paid Shares
Expiry of options
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
+ See chapter 19 for defined terms.
Page 2
01/01/2011
Appendix 3Y
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
If prior written clearance was provided, on what date was this
provided?
No
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
PharmAust Limited
ABN
35 094 006 023
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Mr Robert Charles Bishop
Date of last notice
7 July 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
The securities are held by Longbow Croft
Capital Pty Ltd and First Capital Markets
Pty Limited.
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
No. of securities held prior to change
Mr Bishop is the sole shareholder and
director of Longbow Croft Capital Pty
Ltd and First Capital Markets Pty Limited.
31 October 2023
Class
9,511,060 Ordinary Fully Paid Shares
2,302,766 Listed Options 31/10/2023 – 20c
150,000 Unlisted Options 30/04/26 – 15c
Listed Options 31/10/2023 – 20c
Number acquired
Nil
Number disposed
2,302,766
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
9,511,060 Ordinary Fully Paid Shares
150,000 Unlisted Options 30/04/26 – 15c
Expiry of Listed Options
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
+ See chapter 19 for defined terms.
Page 2
01/01/2011
Appendix 3Y
Appendix 3Y
Change of Director’s Interest Notice
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
If prior written clearance was provided, on what date was this
provided?
No
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 3
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
PharmAust Limited
ABN
35 094 006 023
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Mr Sam Michael Wright
Date of last notice
7 July 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
The securities are held by Straight Lines
Consultancy Pty Ltd as trustee for the
Straight Lines Trust. Mr Wright is a Director
of Straight Lines Consultancy Pty Ltd and
a Beneficiary of the Straight Lines Trust.
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
No. of securities held prior to change
31 October 2023
Class
4,550,000 Ordinary Fully Paid Shares
875,000 Listed Options 31/10/2023 – 20c
250,000 Unlisted Options 30/04/26 – 15c
Listed Options 31/10/2023 – 20c
Number acquired
Nil
Number disposed
875,000
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
4,550,000 Ordinary Fully Paid Shares
250,000 Unlisted Options 30/04/26 – 15c
Expiry of Listed Options
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
If prior written clearance was provided, on what date was this
provided?
No
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
PharmAust Limited
ABN
35 094 006 023
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Mr Neville Bassett
Date of last notice
7 July 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
Shares are held by Mandevilla Pty Ltd. Mr
Bassett is a director and shareholder of
Mandevilla Pty Ltd.
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
No. of securities held prior to change
31 October 2023
Class
507,000 Ordinary Fully Paid Shares
1,750 Listed Options 31/10/2023 – 20c
250,000 Unlisted Options 30/04/26 – 15c
Listed Options 31/10/2023 – 20c
Number acquired
Nil
Number disposed
1,750
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
507,000 Ordinary Fully Paid Shares
250,000 Unlisted Options 30/04/26 – 15c
Expiry of Listed Options
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
If prior written clearance was provided, on what date was this
provided?
No
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Share your feedback
Discover